Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/9691
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJ. Karbwangen_US
dc.contributor.authorK. Na-Bangchangen_US
dc.contributor.authorA. Thanavibulen_US
dc.contributor.authorD. Bunnagen_US
dc.contributor.authorT. Chongsuphajaisiddhien_US
dc.contributor.authorT. Harinasutaen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-02-27T04:28:00Z-
dc.date.available2018-02-27T04:28:00Z-
dc.date.issued1994-05-25en_US
dc.identifier.citationBulletin of the World Health Organization. Vol.72, No.2 (1994), 233-238en_US
dc.identifier.issn00429686en_US
dc.identifier.other2-s2.0-0028200749en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0028200749&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/9691-
dc.description.abstractIn Thailand Plasmodium falciparum malaria is highly resistant to available antimalarials. Investigations on the efficacy of existing antimalarials and of alternative drugs are urgently needed. Artesunate has heen shown to be effective against falciparum malaria, but is associated with a high recrudescence rate. We have carried out a comparative clinical trial of the standard regimen of quinine + tetracycline versus oral artesunate at a 700-mg total dose given over 5 days to patients with acute uncomplicated falciparum malaria. The 64 male patients who took part in the study were randomixed to receive either quinine-tetracycline (33 patients) or oral artesunate (31 patients). All the patients were admitted to the Bangkok Hospital for Tropical Diseases for 28 days. Oral artesunate had faster parasite and fever clearance times than the combination quinine-tetracycline, but the cure rate was not significantly different for the fwo regimens. However, the occurrence of adverse effects, such as tinnitus, was significantly higher in the quinine-tetracycline group. Surprisingly nausea and dizziness were rather common with artesunate. The possibility of neurological adverse effects for artesunate should also be borne in mind. Oral artesunate (700 mg given over 5 days) is effective and better tolerated than the combination quinine-tetracycline. The cure rate we obtained is higher than that reported in previous studies with 600 mg of oral artesunate given over 5 days. Oral artesunate can be considered as an alternative drug for multigle-drug-resistant falciparum malaria; however, adverse effects, particularly neurotoxicity, should be closely monitored before its widespread use can be recommended. In areas where artesunate is not available, the use of quinine-tetracycline for 7 days is still very effective if its administration can be supervised.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0028200749&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleComparison of oral artesunate and quinine plus tetracycline in acute uncomplicated falciparum malariaen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.